Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-07-14

AUTHORS

Marcella Curone, Vincenzo Tullo, Henri Albert Didier, Gennaro Bussone

ABSTRACT

BackgroundMigraine is a disabling primary headache disorder with socioeconomic burden. Medication overuse headache (MOH) is caused by chronic overuse of symptomatic drugs often observed in migraine patients. The approved for migraine prevention CGRP antagonists erenumab, fremanezumab, and galcanezumab are effective in migraine prophylaxis but there are only few data regarding efficacy on MOH.Aim of the studyTo assess efficacy of erenumab, galcanezumab, and fremanezumab in reducing headache in patients with chronic migraine complicated by medication overuse headache.MethodsPatients fitting International Classification of Headache Disorders 3rd Edition criteria for chronic migraine and MOH were enrolled and treated with CGRP antagonists without performing drug withdrawal. Efficacy was assessed by improvement of Migraine Impact and Disability Assessment Scale (MIDAS) and reduction of monthly use of symptomatic medications. Patients reporting a ≥ 50% reduction of monthly headache days and ≥ 50% reduction of analgesic and/or triptan use compared with a 3-month baseline period were defined as responders.ResultsThree hundred three patients, 252 females and 51 males, were enrolled. Patients were treated for at least 6 months up to 1 year. Two hundred forty-two out of 303 (80%) showed both a ≥ 50% reduction of monthly headache days and analgesics intake at 3-month follow-up visit compared to the 3-month baseline period; 239 on 303 (78.8%) continued to have ≥ 50% improvement in both at 6-month follow-up visit.ConclusionMonoclonal antibodies inhibiting CGRP are effective in reducing monthly headache days in migraine patients with MOH. More... »

PAGES

5759-5761

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10072-022-06265-8

DOI

http://dx.doi.org/10.1007/s10072-022-06265-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1149471941

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35836032


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Analgesics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcitonin Gene-Related Peptide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Headache", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Headache Disorders, Secondary", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Migraine Disorders", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Casa Di Cura Privata del Policlinico Igea Headache Center, Via Marcona 69, 20129, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Casa Di Cura Privata del Policlinico Igea Headache Center, Via Marcona 69, 20129, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Curone", 
        "givenName": "Marcella", 
        "id": "sg:person.01122436745.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122436745.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Casa Di Cura Privata del Policlinico Igea Headache Center, Via Marcona 69, 20129, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Casa Di Cura Privata del Policlinico Igea Headache Center, Via Marcona 69, 20129, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tullo", 
        "givenName": "Vincenzo", 
        "id": "sg:person.01006210345.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006210345.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dental and Oral Surgery, Headache and Facial Pain Center Fondazione, IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Dental and Oral Surgery, Headache and Facial Pain Center Fondazione, IRCCS Ca\u2019 Granda, Ospedale Maggiore Policlinico, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Didier", 
        "givenName": "Henri Albert", 
        "id": "sg:person.01200557605.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200557605.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Casa Di Cura Privata del Policlinico Igea Headache Center, Via Marcona 69, 20129, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Casa Di Cura Privata del Policlinico Igea Headache Center, Via Marcona 69, 20129, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bussone", 
        "givenName": "Gennaro", 
        "id": "sg:person.01147710611.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147710611.11"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10072-021-05426-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1139368393", 
          "https://doi.org/10.1007/s10072-021-05426-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s10194-020-01173-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1131068416", 
          "https://doi.org/10.1186/s10194-020-01173-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40263-021-00818-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1138111105", 
          "https://doi.org/10.1007/s40263-021-00818-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s10194-018-0955-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111461146", 
          "https://doi.org/10.1186/s10194-018-0955-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10072-020-04690-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1130688463", 
          "https://doi.org/10.1007/s10072-020-04690-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-07-14", 
    "datePublishedReg": "2022-07-14", 
    "description": "Abstract\nBackgroundMigraine is a disabling primary headache disorder with socioeconomic burden. Medication overuse headache (MOH) is caused by chronic overuse of symptomatic drugs often observed in migraine patients. The approved for migraine prevention CGRP antagonists erenumab, fremanezumab, and galcanezumab are effective in migraine prophylaxis but there are only few data regarding efficacy on MOH.Aim of the studyTo assess efficacy of erenumab, galcanezumab, and fremanezumab in reducing headache in patients with chronic migraine complicated by medication overuse headache.MethodsPatients fitting International Classification of Headache Disorders 3rd Edition criteria for chronic migraine and MOH were enrolled and treated with CGRP antagonists without performing drug withdrawal. Efficacy was assessed by improvement of Migraine Impact and Disability Assessment Scale (MIDAS) and reduction of monthly use of symptomatic medications. Patients reporting a\u2009\u2265\u200950% reduction of monthly headache days and\u2009\u2265\u200950% reduction of analgesic and/or triptan use compared with a 3-month baseline period were defined as responders.ResultsThree hundred three patients, 252 females and 51 males, were enrolled. Patients were treated for at least 6\u00a0months up to 1\u00a0year. Two hundred forty-two out of 303 (80%) showed both a\u2009\u2265\u200950% reduction of monthly headache days and analgesics intake at 3-month follow-up visit compared to the 3-month baseline period; 239 on 303 (78.8%) continued to have\u2009\u2265\u200950% improvement in both at 6-month follow-up visit.ConclusionMonoclonal antibodies inhibiting CGRP are effective in reducing monthly headache days in migraine patients with MOH.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10072-022-06265-8", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1294956", 
        "issn": [
          "1590-1874", 
          "1126-5442"
        ], 
        "name": "Neurological Sciences", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "43"
      }
    ], 
    "keywords": [
      "medication overuse headache", 
      "monthly headache days", 
      "overuse headache", 
      "headache days", 
      "migraine patients", 
      "chronic migraine", 
      "headache disorders", 
      "efficacy of erenumab", 
      "chronic migraine patients", 
      "Disability Assessment Scale", 
      "baseline period", 
      "primary headache disorders", 
      "migraine prophylaxis", 
      "symptomatic medications", 
      "symptomatic drugs", 
      "triptan use", 
      "three patients", 
      "drug withdrawal", 
      "socioeconomic burden", 
      "CGRP antagonist", 
      "chronic overuse", 
      "Edition criteria", 
      "migraine impact", 
      "International Classification", 
      "patients", 
      "headache", 
      "erenumab", 
      "Assessment Scale", 
      "monthly use", 
      "CGRP", 
      "efficacy", 
      "migraine", 
      "follow", 
      "visits", 
      "disorders", 
      "days", 
      "MethodsPatients", 
      "prophylaxis", 
      "BackgroundMigraine", 
      "medications", 
      "analgesics", 
      "antagonist", 
      "studyTo", 
      "responders", 
      "months", 
      "antibodies", 
      "drugs", 
      "reduction", 
      "period", 
      "withdrawal", 
      "burden", 
      "males", 
      "overuse", 
      "females", 
      "improvement", 
      "years", 
      "use", 
      "criteria", 
      "data", 
      "classification", 
      "effectiveness", 
      "impact", 
      "scale"
    ], 
    "name": "Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients", 
    "pagination": "5759-5761", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1149471941"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10072-022-06265-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35836032"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10072-022-06265-8", 
      "https://app.dimensions.ai/details/publication/pub.1149471941"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_933.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10072-022-06265-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10072-022-06265-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10072-022-06265-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10072-022-06265-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10072-022-06265-8'


 

This table displays all metadata directly associated to this object as RDF triples.

215 TRIPLES      21 PREDICATES      105 URIs      92 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10072-022-06265-8 schema:about N163a17d44a3f4a33b6cc7afb23f0bffd
2 N21963eab416d40aba0f977f1c904e1ed
3 N4ec5a10ae10e470c958fb2a0def39fff
4 N78a8ba01ea67495da3424d127342024d
5 N9a5c6a7bb6a34967914fd0841641b8a8
6 Nbad7f7faaa6c4082be8ed40aeab84a26
7 Nd9c3f0c0fae748be9d741dd19c52190e
8 Nea49a3fdc39a4a8f93a7b64e34a40cc1
9 Nf07abc8a7a5b41e5acbc0cdf4843d3ea
10 Nf644f94785bf497199257d589400ace0
11 Nfdabcb72c6474bf99071f6427fabc42f
12 Nfee375bfb1a7479bb14400a7333cfafd
13 anzsrc-for:11
14 anzsrc-for:1117
15 schema:author N1d244c3304124e97b9de5a8b5d95d030
16 schema:citation sg:pub.10.1007/s10072-020-04690-1
17 sg:pub.10.1007/s10072-021-05426-5
18 sg:pub.10.1007/s40263-021-00818-9
19 sg:pub.10.1186/s10194-018-0955-y
20 sg:pub.10.1186/s10194-020-01173-8
21 schema:datePublished 2022-07-14
22 schema:datePublishedReg 2022-07-14
23 schema:description Abstract BackgroundMigraine is a disabling primary headache disorder with socioeconomic burden. Medication overuse headache (MOH) is caused by chronic overuse of symptomatic drugs often observed in migraine patients. The approved for migraine prevention CGRP antagonists erenumab, fremanezumab, and galcanezumab are effective in migraine prophylaxis but there are only few data regarding efficacy on MOH.Aim of the studyTo assess efficacy of erenumab, galcanezumab, and fremanezumab in reducing headache in patients with chronic migraine complicated by medication overuse headache.MethodsPatients fitting International Classification of Headache Disorders 3rd Edition criteria for chronic migraine and MOH were enrolled and treated with CGRP antagonists without performing drug withdrawal. Efficacy was assessed by improvement of Migraine Impact and Disability Assessment Scale (MIDAS) and reduction of monthly use of symptomatic medications. Patients reporting a ≥ 50% reduction of monthly headache days and ≥ 50% reduction of analgesic and/or triptan use compared with a 3-month baseline period were defined as responders.ResultsThree hundred three patients, 252 females and 51 males, were enrolled. Patients were treated for at least 6 months up to 1 year. Two hundred forty-two out of 303 (80%) showed both a ≥ 50% reduction of monthly headache days and analgesics intake at 3-month follow-up visit compared to the 3-month baseline period; 239 on 303 (78.8%) continued to have ≥ 50% improvement in both at 6-month follow-up visit.ConclusionMonoclonal antibodies inhibiting CGRP are effective in reducing monthly headache days in migraine patients with MOH.
24 schema:genre article
25 schema:isAccessibleForFree false
26 schema:isPartOf N0def3d898ace44f69179e3d2ff84c460
27 N155b53b543a94fc3974ab2fc3fca66ba
28 sg:journal.1294956
29 schema:keywords Assessment Scale
30 BackgroundMigraine
31 CGRP
32 CGRP antagonist
33 Disability Assessment Scale
34 Edition criteria
35 International Classification
36 MethodsPatients
37 analgesics
38 antagonist
39 antibodies
40 baseline period
41 burden
42 chronic migraine
43 chronic migraine patients
44 chronic overuse
45 classification
46 criteria
47 data
48 days
49 disorders
50 drug withdrawal
51 drugs
52 effectiveness
53 efficacy
54 efficacy of erenumab
55 erenumab
56 females
57 follow
58 headache
59 headache days
60 headache disorders
61 impact
62 improvement
63 males
64 medication overuse headache
65 medications
66 migraine
67 migraine impact
68 migraine patients
69 migraine prophylaxis
70 monthly headache days
71 monthly use
72 months
73 overuse
74 overuse headache
75 patients
76 period
77 primary headache disorders
78 prophylaxis
79 reduction
80 responders
81 scale
82 socioeconomic burden
83 studyTo
84 symptomatic drugs
85 symptomatic medications
86 three patients
87 triptan use
88 use
89 visits
90 withdrawal
91 years
92 schema:name Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients
93 schema:pagination 5759-5761
94 schema:productId N0e8da105db42489db0bc3efc2bf9c250
95 N42c38609c13546c2888634368e31387b
96 N64de6de439b14db88ee64af41413fa84
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1149471941
98 https://doi.org/10.1007/s10072-022-06265-8
99 schema:sdDatePublished 2022-10-01T06:50
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N08eda8fb494e4d62907aba4531158686
102 schema:url https://doi.org/10.1007/s10072-022-06265-8
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N08eda8fb494e4d62907aba4531158686 schema:name Springer Nature - SN SciGraph project
107 rdf:type schema:Organization
108 N0def3d898ace44f69179e3d2ff84c460 schema:volumeNumber 43
109 rdf:type schema:PublicationVolume
110 N0e8da105db42489db0bc3efc2bf9c250 schema:name doi
111 schema:value 10.1007/s10072-022-06265-8
112 rdf:type schema:PropertyValue
113 N155b53b543a94fc3974ab2fc3fca66ba schema:issueNumber 9
114 rdf:type schema:PublicationIssue
115 N163a17d44a3f4a33b6cc7afb23f0bffd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Migraine Disorders
117 rdf:type schema:DefinedTerm
118 N1d244c3304124e97b9de5a8b5d95d030 rdf:first sg:person.01122436745.95
119 rdf:rest N5dc820a1dde145af9787a02fa5c7d548
120 N21963eab416d40aba0f977f1c904e1ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Humans
122 rdf:type schema:DefinedTerm
123 N42c38609c13546c2888634368e31387b schema:name pubmed_id
124 schema:value 35836032
125 rdf:type schema:PropertyValue
126 N4ec5a10ae10e470c958fb2a0def39fff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Male
128 rdf:type schema:DefinedTerm
129 N5dc820a1dde145af9787a02fa5c7d548 rdf:first sg:person.01006210345.16
130 rdf:rest N6f5c0c9c4c77446d846165bfde6a4b0c
131 N64de6de439b14db88ee64af41413fa84 schema:name dimensions_id
132 schema:value pub.1149471941
133 rdf:type schema:PropertyValue
134 N6f5c0c9c4c77446d846165bfde6a4b0c rdf:first sg:person.01200557605.25
135 rdf:rest N81b5bedfd49d490998ed47ddd463b5b1
136 N78a8ba01ea67495da3424d127342024d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Double-Blind Method
138 rdf:type schema:DefinedTerm
139 N81b5bedfd49d490998ed47ddd463b5b1 rdf:first sg:person.01147710611.11
140 rdf:rest rdf:nil
141 N9a5c6a7bb6a34967914fd0841641b8a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Headache
143 rdf:type schema:DefinedTerm
144 Nbad7f7faaa6c4082be8ed40aeab84a26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Female
146 rdf:type schema:DefinedTerm
147 Nd9c3f0c0fae748be9d741dd19c52190e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Antibodies, Monoclonal, Humanized
149 rdf:type schema:DefinedTerm
150 Nea49a3fdc39a4a8f93a7b64e34a40cc1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Analgesics
152 rdf:type schema:DefinedTerm
153 Nf07abc8a7a5b41e5acbc0cdf4843d3ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Treatment Outcome
155 rdf:type schema:DefinedTerm
156 Nf644f94785bf497199257d589400ace0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Calcitonin Gene-Related Peptide
158 rdf:type schema:DefinedTerm
159 Nfdabcb72c6474bf99071f6427fabc42f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Antibodies, Monoclonal
161 rdf:type schema:DefinedTerm
162 Nfee375bfb1a7479bb14400a7333cfafd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Headache Disorders, Secondary
164 rdf:type schema:DefinedTerm
165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
166 schema:name Medical and Health Sciences
167 rdf:type schema:DefinedTerm
168 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
169 schema:name Public Health and Health Services
170 rdf:type schema:DefinedTerm
171 sg:journal.1294956 schema:issn 1126-5442
172 1590-1874
173 schema:name Neurological Sciences
174 schema:publisher Springer Nature
175 rdf:type schema:Periodical
176 sg:person.01006210345.16 schema:affiliation grid-institutes:None
177 schema:familyName Tullo
178 schema:givenName Vincenzo
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006210345.16
180 rdf:type schema:Person
181 sg:person.01122436745.95 schema:affiliation grid-institutes:None
182 schema:familyName Curone
183 schema:givenName Marcella
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122436745.95
185 rdf:type schema:Person
186 sg:person.01147710611.11 schema:affiliation grid-institutes:None
187 schema:familyName Bussone
188 schema:givenName Gennaro
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147710611.11
190 rdf:type schema:Person
191 sg:person.01200557605.25 schema:affiliation grid-institutes:None
192 schema:familyName Didier
193 schema:givenName Henri Albert
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200557605.25
195 rdf:type schema:Person
196 sg:pub.10.1007/s10072-020-04690-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130688463
197 https://doi.org/10.1007/s10072-020-04690-1
198 rdf:type schema:CreativeWork
199 sg:pub.10.1007/s10072-021-05426-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1139368393
200 https://doi.org/10.1007/s10072-021-05426-5
201 rdf:type schema:CreativeWork
202 sg:pub.10.1007/s40263-021-00818-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138111105
203 https://doi.org/10.1007/s40263-021-00818-9
204 rdf:type schema:CreativeWork
205 sg:pub.10.1186/s10194-018-0955-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1111461146
206 https://doi.org/10.1186/s10194-018-0955-y
207 rdf:type schema:CreativeWork
208 sg:pub.10.1186/s10194-020-01173-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1131068416
209 https://doi.org/10.1186/s10194-020-01173-8
210 rdf:type schema:CreativeWork
211 grid-institutes:None schema:alternateName Casa Di Cura Privata del Policlinico Igea Headache Center, Via Marcona 69, 20129, Milan, Italy
212 Dental and Oral Surgery, Headache and Facial Pain Center Fondazione, IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy
213 schema:name Casa Di Cura Privata del Policlinico Igea Headache Center, Via Marcona 69, 20129, Milan, Italy
214 Dental and Oral Surgery, Headache and Facial Pain Center Fondazione, IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, via Francesco Sforza 35, 20122, Milan, Italy
215 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...